BLCA - Bladder Back

External References: Wikipedia National Cancer Institute Google Scholar

iCoMut Beta for


Highly significantly mutated genes
TP53
51 patients (51%)
KDM6A
27 patients (27%)
MLL2
26 patients (26%)
ARID1A
25 patients (25%)
PIK3CA
18 patients (18%)
RB1
14 patients (14%)
CDKN1A
13 patients (13%)
ERCC2
13 patients (13%)
STAG2
10 patients (10%)
TBC1D12
10 patients (10%)
RXRA
9 patients (9%)
NFE2L2
9 patients (9%)
C3orf70
7 patients (7%)
Significantly mutated genes
CREBBP
12 patients (12%)
ERBB3
10 patients (10%)
FBXW7
10 patients (10%)
ELF3
8 patients (8%)
FGFR3
8 patients (8%)
TSC1
6 patients (6%)
MGA
6 patients (6%)
EZR
6 patients (6%)
FOXQ1
5 patients (5%)
HRAS
5 patients (5%)
SNX25
4 patients (4%)
Genes near significance
MLL3
24 patients (24%)
MLL
13 patients (13%)
RBM26
8 patients (8%)
ASXL2
7 patients (7%)
TRERF1
7 patients (7%)
BCLAF1
6 patients (6%)
EPHA2
6 patients (6%)
SETD2
6 patients (6%)
AKAP11
5 patients (5%)
DDX5
4 patients (4%)
RHOA
4 patients (4%)
BPI
3 patients (3%)
PHF6
3 patients (3%)
TGFBR2
3 patients (3%)
CDKN2A
3 patients (3%)
Click on a gene to see details.

Notes


• Gene name color indicates: known cancer genes | highly compelling novel candidate cancer genes | other candidates

Data details


Mutation list for BLCA
Q-Q plots for BLCA